Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
Sponsored Content by Amgen
Advertisement
Articles by Sponsored Content by Amgen
Advertisement
Latest Updated Articles
Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies9,10Published: June 17th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5